GlobeNewsWire
18 Aug 2026, 11:45 UTC · 12w ago
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
Impact · against what's priced in
The PermeaDerm-I study provides strong clinical and economic evidence to drive adoption, showing a 70% cost reduction over allografts without sacrificing efficacy. These results create a tangible catalyst for revenue growth by removing both the clinical risk and the cost barrier for hospital administrators.
- RCEL+0.70
No priced-in read yet





